Barinthus(BRNS) - 2024 Q3 - Quarterly Results

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results OXFORD, United Kingdom, November 6, 2024 (GLOBE NEWSWIRE) – Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, provided an overview of business updates and announced financial results for the third quarter of 2024. "We continue our strong execution on our clinical trials, completing enrollmen ...